Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
Delayed Quote. Delayed Xetra - 10/23 11:35:23 am
131.85 EUR   +3.05%
10/21MERCK KGAA : Morgan Stanley reaffirms its Neutral rating
MD
10/21MERCK KGAA : Bernstein reiterates its Neutral rating
MD
10/16Physiomics Wins Contracts With Existing Customers
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
124.3(c) 124.6(c) 125.05(c) 127.95(c) 131.85(c) Last
290 119 352 191 590 424 663 160 662 407 Volume
-0.72% +0.24% +0.36% +2.32% +3.05% Change
More quotes
Financials
Sales 2020 17 304 M 20 524 M 20 524 M
Net income 2020 1 706 M 2 023 M 2 023 M
Net Debt 2020 10 847 M 12 866 M 12 866 M
P/E ratio 2020 32,0x
Yield 2020 1,01%
Sales 2021 18 166 M 21 547 M 21 547 M
Net income 2021 2 113 M 2 506 M 2 506 M
Net Debt 2021 9 085 M 10 775 M 10 775 M
P/E ratio 2021 26,5x
Yield 2021 1,08%
Capitalization 57 325 M 67 857 M 67 994 M
EV / Sales 2020 3,94x
EV / Sales 2021 3,66x
Nbr of Employees 57 523
Free-Float 29,7%
More Financials
Company
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - pharmaceutical products (41.6%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - solutions and products for scientific and biotechnological research... 
Sector
Pharmaceuticals
Calendar
11/05Presentation
More about the company
Notations Surperformance© of Merck KGaA
Trading Rating : Investor Rating :
More Ratings
All news about MERCK KGAA
10/21MERCK KGAA : Morgan Stanley reaffirms its Neutral rating
MD
10/21MERCK KGAA : Bernstein reiterates its Neutral rating
MD
10/16Physiomics Wins Contracts With Existing Customers
DJ
10/15MERCK : Global Head of R&D for Healthcare to Retire
DJ
10/15Global Glycobiology Market to Rise at 14.64% between 2020 and 2027
AQ
10/13MERCK : Launches Cell and Gene Therapy Platform
DJ
10/13MERCK KGAA : Barclays withdraws its Sell rating
MD
10/12Merck KgaA Licenses Genome-Editing Technology to Two Companies
DJ
10/09MERCK : Precigen Shares Gain 20% as Germany's Merck Raises Stake
DJ
10/09MERCK : Raises Precigen Stake to 14.8% With Note Conversion
DJ
10/08MERCK : MilliporeSigma Celebrates Topping-Out Ceremony for New Membrane Producti..
AQ
10/07NOVARTIS : EU must wean itself off Asia for key drug ingredients
RE
10/07MERCK KGAA : - MilliporeSigma Inaugurates New, Upgraded Onsite Industrial Water ..
AQ
10/07MERCK : Majority of generic drug ingredients produced in Asia - study
RE
10/06MERCK : to Outlicense Osteoarthritis Clinical Program for Up to EUR450 Million
DJ
More news
News in other languages on MERCK KGAA
10/21MERCK KGAA : Morgan Stanley neutre sur le dossier
10/21Morgan Stanley belässt Merck KGaA auf 'Equal-weight'
10/21MERCK KGAA : Bernstein est neutre sur le titre
10/21Nachrichten zu Keytruda von Merck KGaA positiv - Bernstein
10/20AKTIEN IM FOKUS : Rekordhochs nach Optimismus von Sartorius und Tochter Stedim
More news
Analyst Recommendations on MERCK KGAA
More recommendations
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 126,24 €
Last Close Price 131,85 €
Spread / Highest target 13,8%
Spread / Average Target -4,25%
Spread / Lowest Target -23,4%
EPS Revisions
Managers
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA25.15%65 811
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD114.69%21 777
KYOWA KIRIN CO., LTD.1.28%13 449
BETTA PHARMACEUTICALS CO., LTD.58.30%6 490
YUHAN CORPORATION27.70%3 299
RECIPHARM AB (PUBL)16.71%1 762